Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy

Frontiers in Cardiovascular Medicine 2026 Open access

Read full text
Authors: Katharina Seuthe, Athanasios Feidakis, Richard Julius Nies, Monique Brüwer, L Pennig, Kenan Kaya, Henrik ten Freyhaus, SE Baldus, Roman Pfister
DOI: 10.3389/fcvm.2025.1639855
Cited by: 1
References: 21

Abstract

Aims To provide real-world data on the symptomatic and hemodynamic response of the myosin inhibitor mavacamten in patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods Patients with HOCM up-titrated to their final mavacamten dose were included. The final dose was defined as (i) 15 mg daily (or 5 mg for poor CYP2C19 metabolizers), (ii) a dose achieving a complete hemodynamic response (LVOT gradient

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Heart Failure Treatment and Management Cardiovascular Function and Risk Factors

Publication details

Journal / source
Frontiers in Cardiovascular Medicine
Publisher
Frontiers Media SA
Volume
12
Pages
1639855–1639855
Publication date
2 January 2026
Language
EN